Bladder cancer remains one of the most common and deadly malignancies worldwide, and researchers continue to hunt for molecular clues that could improve diagnosis, prognosis, and treatment. Now, a team of scientists from Pakistan has turned its attention to a gene that sits at the heart of cellular signaling: PTPN6, which encodes the protein tyrosine phosphatase non-receptor type 6, better known in the literature as SHP-1. In a study published in Discover Biotechnology, the researchers combined large-scale genomic databases with careful statistical analysis to ask a deceptively simple question: what happens to PTPN6 in bladder urothelial carcinoma, abbreviated BLCA, and can its behavior tell clinicians anything useful about a patient’s outlook?
The stakes of this question are considerable. According to GLOBOCAN estimates cited in the study, bladder cancer accounts for roughly 3 percent of all cancer diagnoses globally and ranks as the sixth most common tumor in the United States. Men are diagnosed approximately four times more often than women, and their death rate is similarly elevated. The disease disproportionately affects older adults, with 90 percent of U.S. diagnoses occurring in people over 55 and an average age at diagnosis of 73. Treatment options, ranging from transurethral resection to partial or total bladder removal, chemotherapy, radiation, and immunotherapy, depend heavily on stage, yet even after radical cystectomy, prognostic factors such as tumor grade, lymphovascular invasion, and lymph node metastasis shape survival. Reliable molecular biomarkers that could refine these predictions are urgently needed.
PTPN6 is an intriguing candidate. As a member of the protein tyrosine phosphatase family, it does the opposite of tyrosine kinases: rather than adding phosphate groups to proteins, it removes them. This dephosphorylation activity places PTPN6 in control of critical signaling pathways governing cell proliferation, cell cycle regulation, invasion, and angiogenesis. The gene carries two promoters, P-1 active in epithelial cells and P-2 active in hematopoietic cells, and this dual architecture means its expression can behave very differently depending on tissue context. In blood-forming cells, SHP-1 is abundant; in epithelial cells it is modest. Notably, in carcinomas the pattern appears to invert, with SHP-1 levels rising in epithelial cells and falling in hematopoietic cells, a shift that has fueled debate about whether the gene acts as tumor suppressor or, in some settings, a contributor to malignancy.
To resolve PTPN6’s role in bladder cancer, the research team deployed a multi-pronged bioinformatics strategy. They mined The Cancer Genome Atlas through the UALCAN portal to compare expression between tumor and normal tissue, then stratified the results by patient age, gender, ethnicity, and disease stage. Promoter methylation levels were examined in the same framework, because epigenetic changes, not just mutations, can silence or unleash genes. Survival outcomes were analyzed with the Kaplan-Meier plotter tool, which covers more than 54,000 genes across 21 cancer subtypes, and independently verified using GEPIA2, a web server built on TCGA and the Genotype-Tissue Expression project. Mutation frequency was assessed through cBioPortal, which hosts interactive genomic data from thousands of tumor samples, and the gene’s interaction network was reconstructed with the STRING database before pathway enrichment analysis was performed in DAVID.
The headline finding was unambiguous: PTPN6 was significantly upregulated in bladder tumor tissue compared with healthy controls, with a p-value of 4.9E-6, far below the standard 0.05 significance threshold. The elevated expression held across nearly every subgroup examined. Male patients showed higher upregulation than female patients, though both sexes differed significantly from controls. Asian patients displayed the highest expression levels, followed by Caucasian and African-American patients, hinting at ethnic differences in the molecular biology of the disease that could influence progression and treatment response. Across age groups, the strongest upregulation appeared in patients aged 41 to 60, with all groups except the youngest, aged 21 to 40, showing statistically significant differences from normal tissue.
Perhaps the most striking pattern emerged when the researchers tracked expression across tumor stages. Although PTPN6 was elevated in tumors overall, its expression declined progressively as the disease advanced from stage 1 through stage 3, with only a modest further drop at stage 4. The authors interpret this as evidence that the gene’s activity is linked to malignancy itself, and the stage-specific p-values all fell below 0.05. Because PTPN6 is known to function as a signaling molecule controlling cell division, growth, the mitotic cycle, and neoplastic transformation, this stage-dependent decline suggests that losing PTPN6 expression may accompany, or even enable, the transition toward more aggressive disease.
What drives this dysregulation if not mutation? The methylation data provided a compelling answer. Analysis of the PTPN6 promoter revealed significant hypomethylation in tumors relative to controls, with a p-value of 1.67E-5. Since methylation of promoter regions typically suppresses transcription, reduced methylation offers a plausible epigenetic mechanism for the observed overexpression. The hypomethylation was present at every disease stage, was pronounced in Caucasian samples, and appeared in both genders, with females showing at least as much hypomethylation as males. Intriguingly, hypomethylation levels decreased with age. Bladder tumors are known to harbor widespread DNA hypomethylation alongside focal hypermethylation that silences tumor suppressor genes, and the new data place PTPN6 squarely within this epigenetic landscape.
The survival analysis is where the story becomes clinically provocative, and also more complicated. Using the Kaplan-Meier plotter, the team found that patients with lower PTPN6 expression had significantly worse overall survival than those with higher expression, with a p-value of 8.2E-9 and a hazard ratio of 0.43. In other words, higher PTPN6 strongly predicted better survival, a pattern consistent with the gene acting as a tumor suppressor that restrains pathways promoting cancer cell growth. GEPIA2 confirmed that reduced expression associated with poorer overall survival, although in that dataset the p-value of 0.15 did not reach statistical significance, and a hazard ratio of 0.82 still pointed toward increased risk with low expression. The discrepancy between the two platforms underscores a familiar tension in biomarker research: large integrated datasets can yield robust signals, but independent validation remains essential before clinical deployment.
The mutational analysis added a further layer of nuance. Screening bladder cancer samples through cBioPortal revealed that only about 3 percent of tumors carried alterations in PTPN6, comprising seven amplifications, five truncating mutations of unknown significance, two deep deletions, two structural variants, and a single missense mutation. This relative genetic stability reinforces the idea that PTPN6’s misbehavior in bladder cancer is governed primarily by epigenetic regulation rather than DNA-level damage. The authors recommend next-generation sequencing to fully characterize any mutations that do occur, but the low mutation rate itself is informative: it shifts attention to methylation and other chromatin-level mechanisms as the likely culprits behind aberrant signaling.
Finally, the network and pathway analysis sketched the biological context in which PTPN6 operates. The STRING-derived protein-protein interaction network connected PTPN6 with ten partner genes, and enrichment analysis through DAVID identified overrepresented Gene Ontology categories spanning biological process, molecular function, and cellular component, along with KEGG pathways tied to cancer-relevant signaling. The study’s authors conclude that PTPN6 holds promise as both a diagnostic and prognostic biomarker in bladder cancer, with promoter hypomethylation emerging as a probable driver of its overexpression and its expression level correlating with patient survival. They caution that further work is needed to unravel the precise mechanisms at play, but the prospect is tantalizing: if PTPN6’s protective role can be confirmed and its regulation manipulated, future therapies might one day boost its activity in patients whose tumors have allowed it to fade, turning an epigenetic footnote into a genuine clinical lever against one of the world’s most stubborn cancers.
Subject of Research: The role of PTPN6 gene expression, methylation, and prognosis in bladder cancer
Article Title: Deciphering the role of PTPN6 in aberrant signaling and BLCA prognosis
Article References: Deciphering the role of PTPN6 in aberrant signaling and BLCA prognosis. (n.d.). https://doi.org/10.1007/s44340-025-00037-8
Image Credits: AI Generated
DOI: 10.1007/s44340-025-00037-8
Keywords: PTPN6, bladder cancer, BLCA, SHP-1, promoter methylation, prognostic biomarker, bioinformatics, TCGA, protein tyrosine phosphatase, GEPIA2, UALCAN, survival analysis
Cite Scienmag News
APA MLA Chicago
Juliet Wilcox. (September 23, 2026). PTPN6 Gene Emerges as Potential Prognostic Marker in Bladder Cancer. Scienmag. https://scienmag.com/ptpn6-gene-emerges-as-potential-prognostic-marker-in-bladder-cancer/
Juliet Wilcox. “PTPN6 Gene Emerges as Potential Prognostic Marker in Bladder Cancer.” Scienmag, 23 September 2026, https://scienmag.com/ptpn6-gene-emerges-as-potential-prognostic-marker-in-bladder-cancer/. Accessed 23 September 2026.
Juliet Wilcox. “PTPN6 Gene Emerges as Potential Prognostic Marker in Bladder Cancer.” Scienmag. September 23, 2026. https://scienmag.com/ptpn6-gene-emerges-as-potential-prognostic-marker-in-bladder-cancer/
Copy citation Download RIS
Tags: age-related bladder cancer diagnosisbioinformaticsbladder cancerbladder cancer prognosisbladder cancer treatment and molecular targetsbladder urothelial carcinoma biomarkersBLCAgender differences in bladder cancer incidencegene expression in bladder cancergenomic analysis of bladder cancerGEPIA2molecular markers for bladder cancerpotential prognostic markers for urothelial carcinomaprognostic biomarkerpromoter methylationprotein tyrosine phosphatasePTPN6PTPN6 gene in bladder cancerrole of PTPN6 in cancer progressionSHP-1SHP-1 protein and bladder cancersurvival analysisTCGAUALCAN
